Ascendis Pharma A/S (ASND)
| Market Cap | 14.76B |
| Revenue (ttm) | 998.25M +134.8% |
| Net Income | 571.81M |
| EPS | 9.26 |
| Shares Out | 62.11M |
| PE Ratio | 25.65 |
| Forward PE | 49.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 583,980 |
| Open | 240.00 |
| Previous Close | 240.50 |
| Day's Range | 234.28 - 242.85 |
| 52-Week Range | 216.22 - 250.27 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 293.77 (+23.62%) |
| Earnings Date | May 7, 2026 |
About ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]
Financial Performance
In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $293.77, which is an increase of 23.62% from the latest price.
News
Ascendis Pharma initiated with a Buy at Citi
Citi analyst Eric Joseph initiated coverage of Ascendis Pharma (ASND) with a Buy rating and $355 price target Citi is “impressed” with Yorvipath’s launch and sees potential upside to consensus…
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI
Evercore ISI raised the firm’s price target on Ascendis Pharma (ASND) to $329 from $324 and keeps an Outperform rating on the shares.
Ascendis Pharma price target raised to $345 from $342 at Barclays
Barclays raised the firm’s price target on Ascendis Pharma (ASND) to $345 from $342 and keeps an Overweight rating on the shares post the Q1 report. The company sounds confident…
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
Wells Fargo lowered the firm’s price target on Ascendis Pharma (ASND) to $326 from $330 and keeps an Overweight rating on the shares. The firm notes Yorvipath is on a…
Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15)
Reports Q1 revenue EUR 246.6M, consensus EUR 269.64M. Reports Q1 Yorvipath revenue EUR 197M. Reports Q1 Skytrofa revenue EUR 44M. “The FDA approval of YUVIWEL, our third consecutive TransCon product,…
Ascendis Pharma Earnings Call Transcript: Q1 2026
Q1 2026 saw rapid revenue growth and profitability, driven by the FDA approval of YUVIWEL and strong uptake of YORVIPATH and SKYTROFA. Total revenue reached EUR 247 million, with robust patient and prescriber growth, and a strengthened balance sheet through asset sales and debt redemption.
Ascendis Pharma Reports First Quarter 2026 Financial Results
- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollm...
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at ...
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thur...
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Con...
Ascendis Pharma announces commencement of trading of shares on Nasdaq
Ascendis Pharma (ASND) announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market, replacing the listing of American Depositary Shares.
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq...
Ascendis Pharma price target raised to $292 from $262 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Ascendis Pharma (ASND) to $292 from $262 and keeps a Buy rating on the shares. A physician survey conducted in…
Ascendis Pharma to list ordinary shares directly on Nasdaq
Ascendis Pharma (ASND) plans to list its ordinary shares directly on Nasdaq, effective at the opening of trading on April 20. As part of the transition to a direct listing…
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq f...
Ascendis Pharma announces new data from COACH trial
Ascendis Pharma (ASND) announced new data demonstrating TransCon hGH accelerated TransCon CNP’s benefits beyond linear growth with substantial improvements in arm span, spinal canal dimensions, and lo...
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia
- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community
Ascendis Pharma gets orphan drug exclusivity for Yuviwel, launches in the U.S.
Ascendis Pharma (ASND) announced that Yuviwel was granted orphan drug exclusivity by the FDA and that Yuviwel is now commercially available in the United States.
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses
Ascendis Pharma’s TransCon shows efficacy and safety in Turner Syndrome
Ascendis Pharma (ASND) announced positive Week 52 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. investigating the safety, tolerability, and...
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children - TransCon hGH showed a safety and tolerability pr...
Ascendis Pharma assumed with a Buy at Jefferies
Jefferies assumed coverage of Ascendis Pharma (ASND) with a Buy rating and $290 price target The companyhas three approved products powered by its TransCon platform, the analyst tells investors in…
Ascendis Pharma announces new data from Navepegritide trial
Ascendis Pharma (ASND) “announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent improve...
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated wi...
Ascendis Pharma price target raised to $332 from $325 at Stifel
Stifel raised the firm’s price target on Ascendis Pharma (ASND) to $332 from $325 and keeps a Buy rating on the shares following the accelerated approval of Yuviwel. The firm…